Stock IBRX IMMUNITYBIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Real-time Estimate Cboe BZX
Other stock markets
 03:05:31 2024-06-03 pm EDT 		5-day change 1st Jan Change
6.105 USD -4.91% Intraday chart for ImmunityBio, Inc. -7.78% +21.61%
May. 09 ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline
MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline
MT
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline
MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating
MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance
MT
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating
MT
Piper Sandler Downgrades ImmunityBio to Neutral From Overweight, Cuts Price Target to $4 From $10
MT
Jefferies Starts ImmunityBio at Buy With $8 Price Target
MT
Piper Sandler Adjusts ImmunityBio's Price Target to $10 From $20, Reiterates Overweight Rating
MT
ImmunityBio : Says Phase 2/3 Trial in BCG-Unresponsive Bladder Cancer Patients Achieves Complete Response Rate of 72%
MT
ImmunityBio, Inc. Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with A Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-Free in Phase 2/3 Trial
CI
Nantkwest : Reports Positive Interim Data on Survival Rates from Pivotal Pancreatic Cancer Trials; Shares Hit New 52-Week High
MT
NantKwest, Inc. and ImmunityBio, Inc. Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
CI
ImmunityBio, Inc. Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IBRX Stock
  4. News ImmunityBio, Inc.
  5. Analyst Reco.